News

U.S. Food and Drug Administration Approves Tafasitamab-cxix (MONJUVI) for Diffuse Large B-cell Lymphoma (DLBCL)

On July 31, 2020 the U.S. Food and Drug Administration (FDA) announced it has approved tafasitamab-cxix (MONJUVI, MorphoSys US Inc.), a CD19-directed cytolytic antibody, in combination with lenalidomide (REVLIMID) for adult patients with relapsed or refractory diffuse large B-cell lymphoma…

Global Public Relations Executive Joins Lymphoma Research Foundation Board of Directors

Lymphoma Research Foundation Elects Allison+Partners Co-Founder Scott Pansky to Esteemed Board

LRF CEO Meghan Gutierrez Appointed to American Board of Internal Medicine Specialty Board

The American Board of Internal Medicine (ABIM) has ABIM has 12 Specialty Boards - one for all disciplines solely sponsored and administered by ABIM. The Specialty Boards are where the frontline work at the discipline-specific level is done.

U.S. Food and Drug Administration Approves First CAR T Cell Therapy for Mantle Cell Lymphoma: Brexucabtagene Autoleucel (TECARTUS)

Brexucabtagene autoleucel (TECARTUS, Kite, a Gilead Company) has been approved for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). This is the first chimeric antigen receptor (CAR) T cell therapy approved for MCL.

Steven Eichberg Elected Chair of LRF Board of Directors

Eichberg, a Board member since 2019, assumed his new duties from outgoing Chair Michael Werner, whose four-year term concluded on June 30.

LRF Scientific Advisory Board Gains New International Leaders in Lymphoma

The Lymphoma Research Foundation (LRF) welcomes three new members to their elite Scientific Advisory Board (SAB). The new members represent distinct specialties that will contribute to the international impact of the Lymphoma Research Foundation.

Lymphoma Research Foundation Hosts Inaugural Swirl: America, An At Home Tasting Virtual Fundraiser

LRF Spokesperson and acclaimed journalist Lisa Guerrero kicks off nationwide cheeseboard challenge to drive lymphoma awareness.

U.S. Food and Drug Administration Approves Selinexor (XPOVIO) for Diffuse Large B-cell Lymphoma

Selinexor (XPOVIO, Karyopharm Therapeutics, Inc.) is a single-agent oral tablet approved for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma (FL), after at least 2 lines of systemic therapy.

U.S. Food and Drug Administration Approves Tazemetostat (TAZVERIK) and EZH2 Mutation Test for Follicular Lymphoma

Tazemetostat (TAZVERIK), an EZH2 inhibitor, and the EZH2 Mutation Test were granted approval for adult patients with relapsed or refractory follicular lymphoma (FL).

Meet the 2020 Lymphoma Clinical Mentoring Program Scholars

The new class of LRF Scholars is pursuing research projects covering a diverse range of lymphoma subtypes with a goal to improve patient outcomes.

Subscribe to Our Emails. Get lymphoma and CLL resources and updates.